Summit Therapeutics SMMT
United StatesHealthcare · BiotechnologyUSD
29.73 USD (+65.7%)
13 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Summit Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for infectious and oncological diseases, with no marketed products and zero revenue.
Key points
from its scores- ✓Favourable backdrop8.7
- ✕Little competitive advantage0.8
- ✕Demanding valuation0.8
- ✕Poor share-price trend1.0
AI analysis
bottom line, main risk, context and newsAvoid until there is efficacy data from its trials or a regulatory approval; the risk profile is extreme.
Summit Therapeutics is a pre-commercial biotech with a healthy balance sheet (net debt/EBITDA of 0.77) but intense cash burn (ROE of -192.5%) and no revenue, making it a high-risk investment that depends on the success of its clinical trials.
The main risk is regulatory and business model: the failure of a clinical trial or the non-approval of its lead product by the FDA would destroy the company's value.
Context and risks
Pre-commercial biotech company with no revenue, an ROE of -192.5% and zero operating margin, reflecting typical cash burn.
Is Summit Therapeutics stock cheap or expensive?
at the analysis date| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 22.6 | 4.1 | +450% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 29.73 USD, +65.7% versus the price.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −15.8
- EV / EBITDA
- −15.0
- Price / book
- 22.6
- Market cap
- 14.3B USD
- Enterprise value
- 13.1B USD
Profitability
- ROE
- −192.5%
- ROA
- −101.6%
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
- Free cash flow
- −139.7M USD
- FCF yield
- −1.0%
Solvency
- Total debt
- 20.4M USD
- Net debt
- −670.3M USD
- Cash
- 690.7M USD
- EBITDA
- −874.7M USD
- Net debt / EBITDA
- 0.77
- Debt / equity
- 3.24
- Current ratio
- 6.96
- Quick ratio
- 6.67
Growth
- EPS (TTM)
- −1.11 USD
- EPS (forward)
- −1.14 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- −1.52
- Analyst consensus
- Buy (13)
- Target price
- 29.73 USD
- 52-week range
- 12.07 – 29.23
Recent news
All SMMT news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Summit Therapeutics
Is Summit Therapeutics stock cheap or expensive?
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 29.73 USD, +65.7% versus the price. This is not investment advice.
What score does Summit Therapeutics get on MeridIAn Screener?
It scores 2.9 out of 10, rank 2,095 of 2,130 (better than 2% of the companies analysed). Its strongest category is Risk & Context (8.7) and its weakest, Quality / Moat (0.8). Analysis of 08/10/2026.
How much is Summit Therapeutics worth on the stock market?
Its market capitalisation is 14.3B USD and its enterprise value, debt included, is 13.1B USD.
How much debt does Summit Therapeutics have?
It has more cash than debt: net cash of 670.3M USD.
Does Summit Therapeutics pay a dividend?
It pays no dividend, or almost none.
How has Summit Therapeutics stock performed over the last year?
It has fallen 15.9% over the last year, excluding dividends. Over the last 52 weeks it has traded between 12.07 and 29.23 USD. Past performance does not guarantee future results.
What do analysts think of Summit Therapeutics?
13 analysts cover it; their average recommendation is “Buy” and their average target is 29.73 USD (+65.7% versus the price). It is an estimate, not market data.